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ABSTRACT  
Acute pancreatitis (AP) is a common emergency resulting from inflammation of the pancreas. The mechanism involves premature activation of 
enzyme precursors in the acinar cells triggering a self-digestive inflammatory cascade.  Hypertriglyceridemia is the most common etiology of 
pancreatitis after gall stones and alcohol.  It usually follows a sudden surge such as diabetic ketoacidosis on top of heredi tary hyperlipidemia.  
In the present case report; we describe a patient with type-I diabetes mellitus who had developed recurrent attacks of hypertriglyceridemia AP 
(HTG-AP) despite Fenfibrate-therapy and report on our experience with Evolocumab in his treatment and prophylaxis.   
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INTRODUCTION 
Acute pancreatitis (AP) is a common emergency resulting 
from inflammation of the pancreas. It presents with the 
cardinal features of acute upper abdominal pain radiating to 
the back, elevated levels of the pancreatic enzymes amylase 
and lipase, and characteristic features on imaging [1]. The 
mechanism involves premature activation of enzyme 
precursors in the acinar cells triggering a self-digestive 
inflammatory cascade.  Pancreatic enzymes such as 
trypsinogen are synthesized and stored in an inactive – 
hence harmless – form, and are activated upon release into 
the lumen of the duodenum via the action of enterokinases 
[2].  Premature activation may occur for a variety of reasons 
with gall stones and alcohol being the most common.  Genetic 
factors, toxins (alcohol and organophosphate insecticides), 
drugs (steroids, thiazides, beta-blockers, protease inhibitors, 
azathioprine and DPP-4 anti-diabetic agents), metabolic 
(hypercalcemia, obesity, hypothyroidism and 
hypertriglyceridemia), structural damage to pancreatic duct 
post-ERCP and infections (mumps) account for the rest [3].  
Hyperlipidemia in the form of hypertriglyceridemia or 
chylomicronemia, accounts for 7% of the AP cases and is the 
most common after gall stones and alcohol [4].  In the 
present case report; we describe a patient who had recurrent 
attacks of hypertriglyceridemia AP (HTG-AP) and provide a 
useful measure of treatment and prophylaxis. 
THE CASE: 
A 30-year-man presented with severe and progressive 
epigastric pain radiating to the back for 1 week.  The latter 
was associated with recurrent vomiting, abdominal 
distension and inability to lie down.  He had similar attacks 
in the past 6 months.  His family members had similar 
history and hyperlipidemia.  His body weight was 60 kg.  He 
was afebrile with blood pressure at 110/70 mm Hg with 
postural hypotension. He had tender and rigid epigastrium, 
with diminished bowel sounds.  Laboratory investigations; 
showed peripheral leukocytic count at 16 X 109/L with 90% 
neutrophils with normal platelets counts and hemoglobin.  
Serum sugar was 20 mmol/L.  Serum urea, creatinine, 
electrolytes and liver functions were normal including 
albumin and bicarbonate.  TSH was normal.  The serum was 
lipemic with total cholesterol at 12 mmol/L, Low-density 
lipoprotein (LDL) cholesterol at 8 mmol/L and triglycerides 
22 mmol/L. Serum amylase was mildly elevated at 170 IU/L 
(Normal: 25-130) yet serum lipase was very high at 834 IU/L 
(Normal: 13-60).  Urine routine and microscopy revealed 4 
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(+) glucose yet without ketoneuria, proteinuria, hematuria 
and pyuria. Ultrasound of the abdomen showed an enlarged 
and edematous pancreas with smooth, ill-defined margins, 
and pancreatic pseudocyst.  The gall bladder and common 
bile duct were normal and without stones.  Computed 
tomogram of the abdomen confirmed the findings and 
confirmed the absence of gall stones and tumor [Figure 1].  
The patient was treated conservatively with nasogastric 
suction, intravenous fluids, broad-spectrum antibiotic 
prophylaxis and narcotics for pain control. Serum glucose 
was controlled with insulin drip.  On the basis of his high 
triglycerides, cholesterol, and VLDL cholesterol, a diagnosis 
of type IIb hyperlipoproteinemia (Familial Combined 
Hyperlipidemia / FCHL) was established.  He received 
Evolocumab (Repatha-Amgen-pharmaceutical comp.) at a 
dose of 140 ug subcutaneously every week.  Within few days, 
the patient had improved was discharged on Lantos at night 
and pre-meals Novorapid injections as well as weekly 
Evolocumab.  B the third week, CT scan of the abdomnen 
showed marked improvement his pancreatitis and reduction 
in the size of his pancreatic pseudocyst  (Fig. 2).  Six weeks 
later; the dose of Evolocumab was spaced to the usual dose 
of 140 ug every 2 weeks.  Subsequently; the patient did not 
have any further AP and his lipid profile remained normal 
(Table 1).  Follow up; CT of the abdomen showed complete 
resolution of his pancreatic disease and its pseudocystic 
formation by 3 months (Fig. 3).  
 
Table 1. Flow chart showing the laboratory parameters during management of the patient with acute pancreatitis (AP).  
       
  
On Evolocumab 140 
ug/week  
 
On Evolocumab 140 ug/2 
weeks 
Serum test 
 
6-months 
before 
 
6-weeks 
before 
 
On 
admission 
 
3-weeks 
later 
 
6-weeks 
later 
 
3-months later 
  
(Previous 
AP) 
   
(Present 
AP) 
      
                          
Amylase 
 
140 
 
55 
 
170 
 
60 
 
70 
 
40 
(25-130 
IU/L) 
            
             
Lipase 
 
340 
 
60 
 
834 
 
140 
 
40 
 
30 
(13-60 IU/L) 
            
             
Triglyceride 
 
10 
 
4 
 
22 
 
3 
 
2.5 
 
1.2 
(0.5-1.3 
mmol/L) 
            
             Total 
cholesterol 
 
8 
 
6 
 
12 
 
4 
 
1.8 
 
2 
(3-5 
mmol/L) 
            
             LDL-
Cholesterol 
 
5 
 
4 
 
8 
 
3 
 
0 
 
0.5 
(2-4 
mmol/L) 
            
             Fasting 
glucose 
 
17 
 
8 
 
20 
 
6 
 
4 
 
5 
(4-6 
mmol/L) 
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Figure 1. Figure 1. Axial (A) and sagittal (B) planes of CT scan of the patient’s abdomen on his initial assessment showing an 
enlarged pancreas (Star) with indistinct margins and reduced density (due to oedema) with surrounding fat stranding and 
thickened Gerota’s fascia.  Note the large pancreatic pseudocyst which is a non-capsulated homogenous peripancreatic fluid 
collection (solid arrow).   
 
 
Figure 2. Figure 2.  Axial (A) and sagittal (B) planes of CT scan of the patient’s abdomen, 3 weeks after Evolocumab treatment, 
showing reduction of pancreatic inflammation (star) and the pancreatic pseudocyst (arrow) sizes.  
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Figure 3. Figure 3.  Axial (A) and sagittal (B) planes of CT scan of the patient’s abdomen, 3 months after Evolocumab treatment, 
showing near normal pancreatic structures (star). 
 
DISCUSSION 
Primary hyperlipidemia is a rare hereditary diseases 
associated with defects in catabolism of lipids.  They are 
classified according to the Fredrickson classification, which 
is based on the pattern of lipoproteins on electrophoresis or 
ultracentrifugation [5].  Our patient had type IIb 
hyperlipoproteinemia (Familial Combined Hyperlipidemia) 
and his AP was precipitated by secondary hyperlipidemic 
surges due to severe hyperglycemia.  HTG-AP is rarely seen 
at levels less than 1,000mg/dL (11.3 mmol/L) [6].  Such 
levels are not seen with secondary causes and hence, a 
primary hyperlipidemic syndrome should be suspected as 
an underlying defect with the secondary cause as a 
facilitator.  With secondary insults in a genetically 
predisposed individual; triglycerides levels exceed 
1,000mg/dL and chylomicrons are almost always present.  
The latter low density particles are very large and can 
obstruct capillaries leading to local ischemia. This local 
damage can expose triglycerides to pancreatic lipases. 
Subsequently, triglycerides are degraded to free fatty acids 
which initiate the cytotoxic injury via the inflammatory 
mediators and free radicals [7].  Interestingly, serum 
amylase may be normal (in 10% of cases) for cases of acute 
or chronic pancreatitis (depleted acinar cell mass) [8].   
The initial conservative management of HTG-AP includes; 
bowel rest, intravenous fluids, and analgesia [9].  However, 
rapid lowering of hyperlipidemia is essential to slow the 
progression of disease.  It can be achieved by correction of 
secondary insult/s and hypolipemic measures.  In our 
patients; control of diabetes by insulin activates catabolism 
of TG by activation of Lipoprotein lipase [10].  The other 
hypolipemic measures include; Fibrates, Statins, Niacin and 
heparin.   Unfortunately, Niacin and Heparin have limited 
role in control of fulminant disease.  Fibrates are considered 
the standard treatment of HTG-AP yet subsequent addition 
of Statins, for hypercholesterolemia, increases the risk of 
rhabdomyelosis [11].  Moreover, since Fibrates are oral 
agents; their benefit is limited in the initial treatment of 
HTG-AP since patients have to be kept on NG suction.  Direct 
removal of lipoproteins by plasmapharesis can be used in 
patients unresponsive to drug therapy [12].  However, 
plasmaphoresis is expensive and is limited to large medical 
centers.  Since, our patient had severe HTG-AP we elected to 
treat him with Evolocumab yet with a modified regimen.  We 
used it every week rather than every 2 weeks to ensure 
faster action.  Our method was safe and efficacious.  It 
decreased the severity of the disease leading to shorter 
duration of illness and les patient’s suffering as well as rapid 
clearance of its complications (pseudocyst formation).    
Evolocumab is a fully human monoclonal antibody that 
inhibits proprotein convertase subtilisin/kexin type 9 
(PCSK9).  The latter is a protein that targets LDL receptors 
for degradation and thereby reduces the liver's ability to 
remove LDL-cholesterol from the blood and can reduce 
triglyceride levels by as much as 70% if given every 2 weeks 
[13].  It is a product of Amgen-pharmaceutical company that 
has been approved by the FDA in 2105 [14]. The efficacy of 
the drug and its safety, in ischemic heart disease, has been 
established in recent clinical studies [15].  However, its use 
in prevention of TG-induced AP has not been reported. 
CONCLUSION:   
Our case report is the first attempt to use Evolocumab in 
treatment of severe TG-induced AP. 
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